Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SET pseudogene 3 (SETP3) is a processed pseudogene, meaning it is a DNA sequence derived from a functional ancestral gene (likely related to the SET gene) that has lost its protein-coding ability due to disabling mutations or lack of core promoters[1][2][4][5]. Pseudogenes like SETP3 are generally considered nonfunctional remnants; while some pseudogenes have been shown to play regulatory roles in gene expression at the level of RNA, there is no evidence that SETP3 does so[2][3][4]. Pseudogenes can complicate molecular genetic studies due to their sequence similarity to functional genes, but they are not direct therapeutic targets[4]. There are no known drugs, clinical biomarkers, safety concerns, or validated disease associations tied to SETP3. In summary, SET pseudogene 3 (SETP3) is not a valid therapeutic or biological target and should be excluded from most target-based analyses[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SET pseudogene 3 (SETP3).